Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VALEANT PHARMACEUTICALS INTL INC T.VRX

"Valeant Pharmaceuticals is a global specialty pharmaceutical firm with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The firm also has a branded generics business that operates primarily in Latin America, Eastern Europe, and Asia."


TSX:VRX - Post by User

Post by MNK3240on Jun 27, 2017 6:24pm
153 Views
Post# 26411142

VRX: Analysts are in action and price down as usual

VRX: Analysts are in action and price down as usual As usual our analyst friends again have started giving their opinions in big newspapers, obviously negative ones so that VRX can't turn around. Nothing against them but the point is that when you have nothing to lose, you can make a big splash with a theory based on your assumptions (whether true or not) that can impact the market in a big way; and many investors end up losing money. How about they own some shares and do due diligence and publish their opinion in big newspapers? 

As as I mentioned before in one of my posts that the financial theories are not pure science, there are alternatives to analyze financial statements. Not to say that opinion is not right but there is always an alternative view point for these issues! The problem is market picks up the bad news way faster than the good news!
=======================================
Wells Fargo analyst David Maris
 weighed in on the notion today, arguing that even if a swap does happen, it does not repair poor business trends or the increasingly unlikelihood that Valeant can deliver the strong earnings growth promised by consensus forecasts.
<< Previous
Bullboard Posts
Next >>